期刊文献+

HPLC-MS/MS测定人血浆中妥舒沙星的浓度 被引量:2

Determination of Tosufloxacin in Plasma by HPLC-MS/MS
原文传递
导出
摘要 目的 建立快速、灵敏测定人体血浆中妥舒沙星浓度的高效液相色谱-串联质谱方法。方法 采用Agilent EclipsePlus C18色谱柱(4.6 mm×150 mm,3.5μm),乙腈(含0.1%甲酸)-5 mmol.L 1甲酸铵水溶液(36∶64)为流动相等度洗脱,流速为0.5 mL.min 1,柱温40℃。采用多重反应监测(MRM)对妥舒沙星(m/z 405.2→387.2)和内标环丙沙星(m/z 332.2→314.2)的测定。结果 妥舒沙星的线性范围为6-2 000 ng.mL 1,回归方程为y=0.183 5x+1.461 9×10 4,r=0.996 2,最低定量下限为6 ng.mL 1(S/N〉5),日内、日间RSD均〈10%,高(1 800 ng.mL 1)、中(750 ng.mL 1)、低(15 ng.mL 1)浓度标准血样的平均回收率分别为97.5%,103.3%,105.9%。结论 该方法灵敏、准确、简单、快速,可用于妥舒沙星的临床血药浓度监测和药动学研究。 OBJECTIVE To establish a rapid and sensitive HPLC-MS/MS method for tosufloxacin in plasma. METHODS Tosufloxacin was extracted with acetonitrile and the residues were analyzed with a HPLC-MS/MS system used Agilent Eclipse Plus Cl8 column(4.6 mm× 150 mm, 3.5 min) with the mobile phase consisted of acetonitrile (0.1% formic acid) with 5 mmol'L-1 ammonium formate(36 : 64), with a flow rate of 0.5 mL·min-1 and temperature of 40℃. Multiple reaction monitoring(MRM) using the precursor to production combinations of m/z 405.2→387.2 and m/z 332.2→314.2 was performed to detect tosufloxacin and the internal standard, respectively. RESULTS The calibration curves for tosufloxacin had good linearity within the range of 6-2 000 ng·mL-1, r=0.996 2. The limits of quantitation for tosufloxacin was 6 ng.mL 1. The intra-day and inter-day precision of variation was 〈10%. The average recoveries for high-, middle-, low-dose of tosufloxacin(1 800, 750, 15 ng·mL-1) were 97.5%, 103.3% and 105.9%, respectively. CONCLUSION The method provides a sensitive, accurate, precise and reliable analytical procedure for clinical monitoring oftosufloxacin plasma and its pharmacokinetic studies.
出处 《中国现代应用药学》 CAS CSCD 2014年第7期846-850,共5页 Chinese Journal of Modern Applied Pharmacy
基金 广东省医学科研基金(A2013523) 广东省自然科学基金面上项目(8151037001000001)
关键词 妥舒沙星 血药浓度 高效液相色谱-串联质谱法 tosufloxacin plasma concentration HPLC-MS/MS
  • 相关文献

参考文献7

二级参考文献19

  • 1匡湘红,周黎明,王浴生,杨芳炬,张淑华,欧真容.司帕沙星和妥舒沙星的体内外抗菌作用研究(英文)[J].中国抗生素杂志,2005,30(5):289-294. 被引量:4
  • 2潘龙华,李小刚.高效液相色谱法测定加替沙星的血药浓度[J].时珍国医国药,2007,18(2):408-408. 被引量:3
  • 3李勇,袁洪,谭鸿毅,刘畅,裴奇,阳国平.高效液相色谱法测定人体内血浆中的妥舒沙星[J].南华大学学报(医学版),2007,35(1):104-106. 被引量:2
  • 4Niki Y.Pharmacokinetics and safety assessment of tosufloxacin tosilate[J].J Infect Chemother,2002,8 (1):1-18.
  • 5Yamaguchi K.Evaluation of in-vitro and in-vivo antibacterial activity of tosufloxacin tosylate[J].J Infect Chemother,2001,7(4):205-217,.
  • 6Aubert G,Pozzetto B,Dorche G.In vitro bactericidal effect of temafloxacin and tosufloxacin against streptococci[J].Pathol Biol,1991,39 (10):1002-1005.
  • 7Kohno S.Clinical assessment of tosufloxacin tosilate[J].J Infect Chemother,2002,8(1):19-27.
  • 8Yasuda T,Watanabe Y,Minami S,et al.Microbiological assay method for T-3262 concentration in body fluids[J].Chemotherapy,1988,36(suppl 9):137-142.
  • 9Minami R,Nakamura C,lnotsume N,et al.Effects of aluminum hydroxide and famotidine on bioavailability of Iosufloxacin in healthy volunteers[J].Antimicrob Agents Chemother,1998,42(2):453-455.
  • 10Appelbaum PC,Hunter PA.The fluoroquinolone antibacterial:past,present,and perspectives[J].Int J Antimicrob Agents,2000,16(1):5-15.

共引文献9

同被引文献20

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部